S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?

ICON Public (ICLR) Stock Forecast, Price & News

$213.03
+4.56 (+2.19%)
(As of 05/31/2023 ET)
Compare
Today's Range
$206.41
$213.41
50-Day Range
$183.12
$215.91
52-Week Range
$171.43
$249.62
Volume
634,370 shs
Average Volume
712,286 shs
Market Capitalization
$17.45 billion
P/E Ratio
34.47
Dividend Yield
N/A
Price Target
$257.30

ICON Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
20.8% Upside
$257.30 Price Target
Short Interest
Healthy
1.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of ICON Public in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.66%
From $11.88 to $13.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

101st out of 1,006 stocks

Commercial Physical Research Industry

5th out of 16 stocks


ICLR stock logo

About ICON Public (NASDAQ:ICLR) Stock

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Stock News Headlines

ICON plc to Attend Upcoming Investor Conferences
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
ICON releases its 2022 ICON Cares ESG Report
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
ICON Public (NASDAQ:ICLR) PT Lowered to $270.00
ICON Public (NASDAQ:ICLR) Shares Down 5.9%
ICON Public (NASDAQ:ICLR) Sees Strong Trading Volume
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
ICON Reports First Quarter 2023 Results
ICON Public (ICLR) Set to Announce Earnings on Wednesday
ICLR ICON Public Limited Company
ICON Public (NASDAQ:ICLR) PT Lowered to $250.00
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Company Calendar

Last Earnings
11/03/2021
Today
5/31/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICLR
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$257.30
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$220.00
Forecasted Upside/Downside
+20.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$505.30 million
Pretax Margin
7.33%

Debt

Sales & Book Value

Annual Sales
$7.74 billion
Cash Flow
$18.99 per share
Book Value
$105.63 per share

Miscellaneous

Free Float
45,880,000
Market Cap
$17.45 billion
Optionable
Optionable
Beta
1.12

Social Links


Key Executives

  • Stephen A. Cutler
    Chief Executive Officer & Executive Director
  • Brendan Brennan
    Chief Financial Officer
  • Tom O'Leary
    Chief Information Officer
  • Gregory P. Licholai
    Chief Medical & Innovation Officer
  • Diarmaid Cunningham
    Secretary, Chief Administrative Officer & EVP













ICLR Stock - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings
or view top-rated stocks.

What is ICON Public's stock price forecast for 2023?

10 brokerages have issued 12 month price targets for ICON Public's shares. Their ICLR share price forecasts range from $220.00 to $280.00. On average, they expect the company's stock price to reach $257.30 in the next twelve months. This suggests a possible upside of 20.8% from the stock's current price.
View analysts price targets for ICLR
or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2023?

ICON Public's stock was trading at $194.25 at the beginning of the year. Since then, ICLR shares have increased by 9.7% and is now trading at $213.03.
View the best growth stocks for 2023 here
.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ICLR earnings forecast
.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) issued its quarterly earnings results on Wednesday, November, 3rd. The medical research company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.39 by $0.16. The medical research company earned $1.87 billion during the quarter, compared to analysts' expectations of $1.84 billion. ICON Public had a net margin of 6.52% and a trailing twelve-month return on equity of 11.16%. ICON Public's revenue was up 166.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $12.40-$13.05 for the period, compared to the consensus earnings per share estimate of $12.67. The company issued revenue guidance of $7.94 billion-$8.34 billion, compared to the consensus revenue estimate of $8.14 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.67%), TimesSquare Capital Management LLC (0.25%), Todd Asset Management LLC (0.17%), Globeflex Capital L P (0.06%), Kornitzer Capital Management Inc. KS (0.05%) and Silvercrest Asset Management Group LLC (0.04%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $213.03.

How much money does ICON Public make?

ICON Public (NASDAQ:ICLR) has a market capitalization of $17.45 billion and generates $7.74 billion in revenue each year. The medical research company earns $505.30 million in net income (profit) each year or $6.18 on an earnings per share basis.

How many employees does ICON Public have?

The company employs 41,100 workers across the globe.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The official website for the company is www.iconplc.com. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page (NASDAQ:ICLR) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -